Protein PHGDH may predict immunotherapy success in colorectal cancer

NCT ID NCT07508046

Completed Knowledge-focused Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study from West China Hospital examined tumor tissue from 100 colorectal cancer patients who had already received immunotherapy. Researchers measured levels of a protein called PHGDH to see if it was linked to how well the patients responded to treatment and how long they lived. The goal was to find a simple marker that could help guide future treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If PHGDH proves to be a reliable marker, doctors could one day use it to decide which colorectal cancer patients are most likely to benefit from immunotherapy.
What could go wrong: This is an observational study that only looks back at existing data. It does not test a new treatment, so any link between PHGDH and outcomes is still unproven and needs much larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLO-RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colonic neoplasm colorectal adenocarcinoma colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLO-RECTAL CANCER

Contacts and locations

Locations

West China Hospital

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.